RxDoctor Payments Data

Ronak Bhimani

Internal Medicine · Norristown, PANPI 1760899975

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $622,742 of the $623,141 with a category attached, or 99.9%. Kedplasma LLC accounts for 99.9% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $225,580, more than ten times the $121 reported in 2020. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$623,141in general payments, 2019–2025

Across 91 payments — averaging $6847.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kedplasma LLC$623K
  • Siemens Medical Solutions USA, Inc.$149
  • AstraZeneca$121
  • Johnson & Johnson$107
  • Vapotherm Inc$21

What the payments were for

  • Consulting fees$622,742100%
  • Food & beverage$3990%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$623,141 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$266,379
Medicare patients
479
Services billed
2,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$19,357
XareltoRivaroxaban18$10,842
JardianceEmpagliflozin18$6,931
BrilintaTicagrelor12$5,303
TradjentaLinagliptin13$3,411
Atorvastatin Calcium170$1,716
LantusInsulin Glargine,hum.Rec.Anlog19$1,344
Divalproex Sodium24$1,159
Buspirone Hcl24$817
Gabapentin39$758
ClopidogrelClopidogrel Bisulfate84$733
Pantoprazole Sodium50$523
Olanzapine17$420
Albuterol Sulfate HfaAlbuterol Sulfate15$406
Oseltamivir Phosphate15$378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$107$10,84218 claims
AstraZenecaBrilinta$121$5,30312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Norristown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →